MedTrace Logo

A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®

NCT00884689 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2011-03-31

No results posted yet for this study

Summary

The purpose of this study is to describe the use of rescue medication and quality of life in adult asthmatic patients, either treated with SYMBICORT SMART® (regular dose according to physician's prescription and the current summary of product characteristics - SPC) or treated with a free combination of ICS plus LABA plus as needed SABA prescribed by the physician.

Conditions

Sponsors & Collaborators

  • ClinResearch, GmbH

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Kai Richter, MD · AstraZeneca

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884689 on ClinicalTrials.gov